Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYR8LF)

• Drug Name: NKTR-262 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
Melanoma	2C30	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMYR8LF

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 7 (TLR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[4]
Hydroxychloroquine	DMSIVND	Chronic renal failure	GB61.Z	Approved	[5]
ANA773	DMSC8YW	Hepatitis C virus infection	1E51.1	Phase 2a	[6]
GS-9620	DMG5C8D	Hepatitis B virus infection	1E51.0	Phase 2	[7]
IMO-3100	DMM549D	Psoriasis vulgaris	EA90	Phase 2	[8]
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[9]
LOXORIBINE	DMIV9ZE	Immune System disease	4A01-4B41	Phase 2	[10]
GSK2245035	DMBWPZJ	Asthma	CA23	Phase 2	[11]
AZD-8848	DM0M7QW	Allergic rhinitis	CA08.0	Phase 2	[12]
Isatoribine	DMHOJ8W	Hepatitis C virus infection	1E51.1	Phase 2	[13]

Drug(s) Targeting Toll-like receptor 8 (TLR8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Resiquimod	DML6XSP	Actinic keratosis	EK90.0	Phase 2	[9]
Selgantolimod	DMST4OR	Hepatitis B	1E51	Phase 2	[14]
Afimetoran	DM3HN3U	Systemic lupus erythematosus	4A40.0	Phase 2	[15]
CPG 52364	DMVDYTG	Systemic lupus erythematosus	4A40.0	Phase 1	[16]
CV8102	DMYD37G	Melanoma	2C30	Phase 1	[17]
MEDI9197	DM0J7UR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
SBT6050	DMHBD3T	Solid tumour/cancer	2A00-2F9Z	Phase 1	[19]
VTX-1463	DM4ZIRK	Allergic rhinitis	CA08.0	Phase 1	[20]
DN1508052	DM0JT9C	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
GSK5251738	DM8Y6DR	Hepatitis B	1E51	Phase 1	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 7 (TLR7)	TTRJ1K4	TLR7_HUMAN	Agonist	[3]
Toll-like receptor 8 (TLR8)	TT8CWFK	TLR8_HUMAN	Agonist	[3]

References

• [1] ClinicalTrials.gov (NCT03435640) A Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) and With Bempegaldesleukin Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies (REVEAL). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of Nektar Therapeutics.
• [4] Imiquimod enhances IFN-gamma production and effector function of T cells infiltrating human squamous cell carcinomas of the skin. J Invest Dermatol. 2009 Nov;129(11):2676-85.
• [5] TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec;6(4):223-35.
• [6] Clinical pipeline report, company report or official report of Anadys Pharmaceuticals (2011).
• [7] Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
• [8] Company report (Iderapharma)
• [9] TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).Vaccine.2005 Nov 1;23(45):5263-70.
• [10] The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol. 2003 Nov;33(11):2987-97.
• [11] Early clinical evaluation of the intranasal TLR7 agonist GSK2245035: Use of translational biomarkers to guide dosing and confirm target engagement. Clin Pharmacol Ther. 2015 Oct;98(4):369-80.
• [12] Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012 Jun 22;13:53.
• [13] Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine. Nucleosides Nucleotides Nucleic Acids. 2007;26(6-7):635-40.
• [14] Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B. J Med Chem. 2020 Sep 24;63(18):10188-10203.
• [15] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
• [16] Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus. Lupus Foundation of America, Inc. 2007.
• [17] Clinical pipeline report, company report or official report of CureVac.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Clinical pipeline report, company report or official report of Silverback Therapeutics.
• [20] VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011 Jul;20(7):981-6.
• [21] Clinical pipeline report, company report or official report of Shanghai De Novo Pharmatech.
• [22] Clinical pipeline report, company report or official report of GlaxoSmithKline